STAT+: FDA approves Merck’s oral PCSK9 drug, a first

The FDA has greenlit Merck’s first-ever oral PCSK9 inhibitor, marking a significant milestone in cholesterol management. This approval could revolutionize how patients with high cholesterol treat their condition, offering a more convenient alternative to existing injectable therapies. Given the rising concerns over heart disease, this development holds substantial implications for public health and the pharmaceutical market, potentially reducing heart attack and stroke risks in high-risk patients. This move by Merck could also spur further innovation in the development of oral treatments for other chronic conditions.